Skip to main content
Premium Trial:

Request an Annual Quote

ABI, Affy, IBM Partner With Mexican Genomic Medicine Institute

NEW YORK, July 19 (GenomeWeb News) - Mexico's Instituto Nacional de Medicina Genomica (INMEGEN) next week will unveil three new units formed in collaboration with Applied Biosystems, Affymetrix, and IBM, INMEGEN said today.


At a ribbon-cutting ceremony to be held next week at the INMEGEN facilities in Mexico City, the institute will open its Applied Biosystems Sequencing and Genotyping Unit, which has partnered with ABI. The institute also will be introducing an Affymetrix Gene Expression Analysis unit, and an IBM Bioinformatics unit, INMEGEN said.


INMEGEN was established in 2004 as part of Mexico's National Institutes of Health to improve the health care of Mexican people by "focusing on the unique genetic makeup of its population, diseases, and conditions that specifically burden Mexican people," the institute said in a statement.


Applied Biosystems and INMEGEN will undertake the largest genotyping study undertaken in Latin America to date as part of their collaboration, INMEGEN said.


Additional details were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.